COPENHAGEN, July 29 (Reuters) - Obesity drugmaker Novo

Nordisk warned on Tuesday that full-year sales and

operating proft would grow less than previously expected,

marking its second forecast cut of 2025.

The maker of weight-loss drug Wegovy is struggling to

convince investors it can remain competitive in the obesity drug

boom against U.S. rival Eli Lilly ( LLY ). Novo shares have

fallen sharply over the past year.